Myocarditis diagnostic study of choice: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Myocarditis}}
{{myocarditis}}
{{CMG}}; {{AE}}
{{CMG}} '''Associate Editor(s)-In-Chief:''' [[Varun Kumar]] M.B.B.S., {{Maliha}}
== Overview ==
 
 


== Diagnostic Study of Choice ==
== Diagnostic Study of Choice ==


=== Study of choice ===
=== Study of choice ===
[Name of the investigation] is the gold standard test for the diagnosis of [disease name].
===Endomyocardial Biopsy===
*The Heart Failure Society of America recommends that performance of [[endomyocardial biopsy]] should be considered when cardiac function deteriorates acutely with an unknown etiology that is unresponsive to medical therapy ''(Strength of Evidence = B)''.<ref name="pmid20610207">{{cite journal| author=Heart Failure Society of America. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA et al.| title=HFSA 2010 Comprehensive Heart Failure Practice Guideline. | journal=J Card Fail | year= 2010 | volume= 16 | issue= 6 | pages= e1-194 | pmid=20610207 | doi=10.1016/j.cardfail.2010.04.004 | pmc= | http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20610207  }} </ref>


OR
*Non-specific findings such as [[hypertrophy]], cell loss, and [[fibrosis]] may be noted on biopsy. However, biopsy findings that significantly impact patient management have not been conclusively established.<ref name="pmid3421562">{{cite journal| author=Chow LC, Dittrich HC, Shabetai R| title=Endomyocardial biopsy in patients with unexplained congestive heart failure. | journal=Ann Intern Med | year= 1988 | volume= 109 | issue= 7 | pages= 535-9 | pmid=3421562 | doi= | pmc= | url= }} </ref> Although inflammatory changes in the myocardium may be detected in viral myocarditis, the majority of patients with biopsy proven myocarditis improve with supportive therapy alone without the need for antiviral or anti-inflammatory treatment.<ref name="pmid7596370">{{cite journal| author=Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME et al.| title=A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. | journal=N Engl J Med | year= 1995 | volume= 333 | issue= 5 | pages= 269-75 | pmid=7596370 | doi=10.1056/NEJM199508033330501 | pmc= | url= }} </ref> Endomyocardial biopsy has a low sensitivity and specificity which could be explained by the focal and transient nature of the inflammatory infiltrates.<ref name="pmid14993139">{{cite journal| author=Mahrholdt H, Goedecke C, Wagner A, Meinhardt G, Athanasiadis A, Vogelsberg H et al.| title=Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. | journal=Circulation | year= 2004 | volume= 109 | issue= 10 | pages= 1250-8 | pmid=14993139 | doi=10.1161/01.CIR.0000118493.13323.81 | pmc= | http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14993139  }} </ref><ref name="pmid2593714">{{cite journal| author=Hauck AJ, Kearney DL, Edwards WD| title=Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error. | journal=Mayo Clin Proc | year= 1989 | volume= 64 | issue= 10 | pages= 1235-45 | pmid=2593714 | doi= | pmc= | url= }} </ref>


The following result of [gold standard test] is confirmatory of [disease name]:
==Standardizing the Interpretation of Endomyocardial Biopsies: The Dallas Criteria==
* [Result 1]
Histologically, both active inflammatory infiltrate within the myocardium and associated myocyte necrosis (the Dallas pathologic criteria) are present in myocarditis. Despite its limitations, the Dallas criteria have established uniform histologic criteria diagnosing myocarditis and have substantially reduced the variability in diagnosing the disease.  Some of the criteria are as follows:<ref name="pmid3455232">{{cite journal| author=Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ et al.| title=Myocarditis. A histopathologic definition and classification. | journal=Am J Cardiovasc Pathol | year= 1987 | volume= 1 | issue= 1 | pages= 3-14 | pmid=3455232 | }} </ref>
* [Result 2]


OR
{{cquote|
====Active myocarditis:====
*The presence of an inflammatory infiltrate of the myocardium with necrosis and/or degeneration of adjacent myocytes not typical of the ischaemic damage associated with [[coronary artery disease]].


[Name of the investigation] must be performed when:
====Borderline myocarditis:====
* The patient presents with [symptom/sign 1], [symptom/sign 2], and [symptom/sign 3].
*The presence of an inflammatory infiltrate of the myocardium without necrosis or degeneration of adjacent myocytes.}}
* A [name of test] is positive for [sign 1], [sign 2], and [sign 3] in the patient.


OR
==Scenarios in Which Endomyocardial Biopsy May Be Useful<ref name="pmid11605687">{{cite journal| author=Wu LA, Lapeyre AC, Cooper LT| title=Current role of endomyocardial biopsy in the management of dilated cardiomyopathy and myocarditis. | journal=Mayo Clin Proc | year= 2001 | volume= 76 | issue= 10 | pages= 1030-8 | pmid=11605687 | doi= | pmc= | url= }} </ref><ref name="pmid16476862">{{cite journal| author=Magnani JW, Dec GW| title=Myocarditis: current trends in diagnosis and treatment. | journal=Circulation | year= 2006 | volume= 113 | issue= 6 | pages= 876-90 | pmid=16476862 | doi=10.1161/CIRCULATIONAHA.105.584532 | pmc= | http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16476862  }} </ref>==


[Name of the investigation] is the gold standard test for the diagnosis of [disease name].


OR
*Subacute or acute symptoms of [[heart failure]] refractory to standard management
*Rapid worsening of [[ejection fraction]] despite standard pharmacological therapy
*Development of cardiac [[arrhythmias]] such as [[ventricular tachycardia]] and/or [[heart block]]
*[[Heart failure]] with concomitant [[rash]], [[fever]], or peripheral [[eosinophilia]]
*Cardiac dysfunction thought to be secondary to the following conditions as the results of endomyocardial biopsy may alter the therapy:
**[[Collagen vascular disease]]s:
***[[Systemic lupus erythematosus]]
***[[Scleroderma]]
***[[Polyarteritis nodosa|Polyarteritis nodosum]]
**Infiltrative diseases:
***[[Amyloidosis]]: These patients are not eligible for [[cardiac  transplantation]].
***[[Sarcoidosis]]
***[[Hemachromatosis]]
**[[Giant cell myocarditis]]: Myocardial biopsy may optimize the management of these patients by identifying patients who may benefit from early [[heart transplantation]].<ref name="pmid9197214">{{cite journal| author=Cooper LT, Berry GJ, Shabetai R| title=Idiopathic giant-cell myocarditis--natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. | journal=N Engl J Med | year= 1997 | volume= 336 | issue= 26 | pages= 1860-6 | pmid=9197214 | doi=10.1056/NEJM199706263362603 | pmc= | url= }} </ref>


The diagnostic study of choice for [disease name] is [name of the investigation].
==Complications of Endomyocardial Biopsy==


OR
*Complications may be as high as 6% as observed in a series where 546 patients with cardiomyopathy underwent right ventricular endomyocardial biopsy.<ref name="pmid1729344">{{cite journal| author=Deckers JW, Hare JM, Baughman KL| title=Complications of transvenous right ventricular endomyocardial biopsy in adult patients with cardiomyopathy: a seven-year survey of 546 consecutive diagnostic procedures in a tertiary referral center. | journal=J Am Coll Cardiol | year= 1992 | volume= 19 | issue= 1 | pages= 43-7 | pmid=1729344 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1729344  }} </ref> Several other studies reported the incidence of complications to be 0.5 to 1.5%.<ref name="pmid20713901">{{cite journal| author=Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C, Athanasiadis A et al.| title=Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. | journal=Circulation | year= 2010 | volume= 122 | issue= 9 | pages= 900-9 | pmid=20713901 | doi=10.1161/CIRCULATIONAHA.109.924167 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20713901  }} </ref><ref name="pmid18838566">{{cite journal| author=Holzmann M, Nicko A, Kühl U, Noutsias M, Poller W, Hoffmann W et al.| title=Complication rate of right ventricular endomyocardial biopsy via the femoral approach: a retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period. | journal=Circulation | year= 2008 | volume= 118 | issue= 17 | pages= 1722-8 | pmid=18838566 | doi=10.1161/CIRCULATIONAHA.107.743427 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18838566  }} </ref>


There is no single diagnostic study of choice for the diagnosis of [disease name].
*Complications of endomyocardial biopsy include:<ref name="pmid20713901">{{cite journal| author=Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C, Athanasiadis A et al.| title=Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. | journal=Circulation | year= 2010 | volume= 122 | issue= 9 | pages= 900-9 | pmid=20713901 | doi=10.1161/CIRCULATIONAHA.109.924167 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20713901  }} </ref><ref name="pmid17959655">{{cite journal| author=Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U et al.| title=The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. | journal=Circulation | year= 2007 | volume= 116 | issue= 19 | pages= 2216-33 | pmid=17959655 | doi=10.1161/CIRCULATIONAHA.107.186093 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17959655  }} </ref>
:*Myocardial perforation leading to [[pericardial tamponade]]
:*[[Heart block]]
:*[[Pulmonary embolization]]
:*[[Pneumothorax]]
:*[[Nerve injury]]
:*[[Hematoma]]
:*[[Tricuspid valve]] damage
:*[[Arteriovenous fistula]]
:*[[Deep venous thrombosis]]
:*[[Bleeding]] at the puncture site (venous/arterial due to accidental arterial puncture)
:*[[Arrhythmias]] ([[supraventricular tachycardia]]/[[ventricular tachycardia]]/[[complete heart block]])
:*[[Tricuspid valve]] damage
:*[[Coronary artery]] to [[right ventricle]] [[fistula]]


OR
== 2009 ACC/AHA Focused Update and 2005 Guidelines for the Diagnosis and Management of Chronic Heart Failure in the Adult (DO NOT EDIT) <ref name="pmid19324967">Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG et al. (2009) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19324967 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.] ''Circulation'' 119 (14):1977-2016. [http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192064 DOI:10.1161/CIRCULATIONAHA.109.192064] PMID: [http://pubmed.gov/19324967 19324967]</ref>==


There is no single diagnostic study of choice for the diagnosis of [disease name], but [disease name] can be diagnosed based on [name of the investigation 1] and [name of the investigation 2].
===Endomyocardial Biopsy in Patients Presenting With Heart Failure (DO NOT EDIT) <ref name="pmid19324967">Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG et al. (2009) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19324967 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.] ''Circulation'' 119 (14):1977-2016. [http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192064 DOI:10.1161/CIRCULATIONAHA.109.192064] PMID: [http://pubmed.gov/19324967 19324967]</ref>===


OR
{|class="wikitable" style="width:80%"
 
|-
[Disease name] is primarily diagnosed based on the clinical presentation.
| colspan="1" style="text-align:center; background:LightCoral"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (No Benefit)
 
|-
OR
| bgcolor="LightCoral"|<nowiki>"</nowiki> '''1.''' Endomyocardial biopsy should not be performed in the routine evaluation of patients with [[heart failure]].<ref name="pmid17959655">{{cite journal| author=Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U et al.| title=The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. | journal=Circulation | year= 2007 | volume= 116 | issue= 19 | pages= 2216-33 | pmid=17959655 | doi=10.1161/CIRCULATIONAHA.107.186093 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17959655  }} </ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
|}


Investigations:
{|class="wikitable" style="width:80%"
* Among the patients who present with clinical signs of [disease name], the [investigation name] is the most specific test for the diagnosis.
* Among the patients who present with clinical signs of [disease name], the [investigation name] is the most sensitive test for diagnosis.
* Among the patients who present with clinical signs of [disease name], the [investigation name] is the most efficient test for diagnosis.
 
==== The comparison of various diagnostic studies for [disease name] ====
{|
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | Test
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Sensitivity
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Specificity
|-
|-
! style="background: #696969; color: #FFFFFF; text-align: center;" |Test 1
| colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |...%
| style="background: #DCDCDC; padding: 5px; text-align: center;" |...%
|-
|-
! style="background: #696969; color: #FFFFFF; text-align: center;" |Test 2
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' Endomyocardial biopsy can be useful in patients presenting with [[heart failure]] when a specific diagnosis is suspected that would influence therapy.<ref name="pmid17959655">{{cite journal| author=Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U et al.| title=The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. | journal=Circulation | year= 2007 | volume= 116 | issue= 19 | pages= 2216-33 | pmid=17959655 | doi=10.1161/CIRCULATIONAHA.107.186093 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17959655  }} </ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |...%
| style="background: #DCDCDC; padding: 5px; text-align: center;" |...%
|}
|}
<small> [Name of test with higher sensitivity and specificity] is the preferred investigation based on the sensitivity and specificity</small>


===== Diagnostic results =====
==2007 AHA/ACCF/ESC Scientific Statement: The Role of Endomyocardial Biopsy (EMB) in Fourteen Clinical Scenarios<ref name="pmid17959655">{{cite journal| author=Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U et al.| title=The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. | journal=Circulation | year= 2007 | volume= 116 | issue= 19 | pages= 2216-33 | pmid=17959655 | doi=10.1161/CIRCULATIONAHA.107.186093 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17959655  }} </ref>==
The following finding(s) on performing [investigation name] is(are) confirmatory for [disease name]:
* [Finding 1]
* [Finding 2]


===== Sequence of Diagnostic Studies =====
{|class="wikitable" style="width:80%"
The [name of investigation] must be performed when:
|-
* The patient presented with symptoms/signs 1, 2, and 3 as the first step of diagnosis.
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
* A positive [test] is detected in the patient, to confirm the diagnosis.


OR
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' EMB should be performed in the setting of unexplained, new-onset [[heart failure]] of less than 2 weeks’ duration associated with a normal-sized or [[dilated left ventricle]] and hemodynamic compromise. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki>


The various investigations must be performed in the following order:
|-
* [Initial investigation]
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' EMB should be performed in the setting of unexplained, new-onset [[heart failure]] of 2 weeks’ to 3 months’ duration associated with a dilated left ventricle and new [[ventricular arrhythmias]], second- or third-degree [[heart block]], or failure to respond to usual care within 1 to 2 weeks. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki>
* [2nd investigation]
|}


=== Name of Diagnostic Criteria ===
{|class="wikitable" style="width:80%"
|-
|colspan="1" style="text-align:center; background:LightCoral"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (No Benefit)
|-
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' EMB should not be performed in the setting of unexplained [[atrial fibrillation]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
|}


'''It is recommended that you include the criteria in a table. Make sure you always cite the source of the content and whether the table has been adapted from another source.'''
{|class="wikitable" style="width:80%"
|-
| colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]
|-
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' EMB is reasonable in the clinical setting of unexplained [[heart failure]] of more than 3 months’ duration associated with a [[dilated left ventricle]] and new [[ventricular arrhythmias]], [[Second degree AV block|second-]] or [[Third degree AV block|third-degree]] [[heart block]], or failure to respond to usual care within 1 to 2 weeks. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
|-
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' EMB is reasonable in the setting of unexplained [[heart failure]] associated with a [[Dilated cardiomyopathy|dilated cardiomyopathy (DCM)]] of any duration associated with suspected allergic reaction and/or [[eosinophilia]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
|-
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''3.''' EMB is reasonable in the setting of unexplained [[heart failure]] associated with suspected [[anthracycline]] [[cardiomyopathy]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
|-
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''4.''' EMB is reasonable in the setting of [[heart failure]] associated with unexplained [[restrictive cardiomyopathy]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
|-
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''5.''' EMB is reasonable in the setting of suspected [[cardiac tumor]]s. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
|-
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''6.''' EMB is reasonable in the setting of unexplained [[cardiomyopathy]] in children. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
|}


[Disease name] is primarily diagnosed based on clinical presentation. There are no established criteria for the diagnosis of [disease name].
{|class="wikitable" style="width:80%"
 
|-
OR
| colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]]
 
|-
There is no single diagnostic study of choice for [disease name], though [disease name] may be diagnosed based on [name of criteria] established by [...].
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' EMB may be considered in the setting of unexplained, new-onset [[heart failure]] of 2 weeks’ to 3 months’ duration associated with a [[dilated left ventricle]], without new [[ventricular arrhythmias]] or [[Second degree AV block|second-]] or [[Third degree AV block|third-degree]] [[heart block]], that responds to usual care within 1 to 2 weeks. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki>
 
|-
OR
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.''' EMB may be considered in the setting of unexplained [[heart failure]] of more than 3 months’ duration associated with a [[dilated left ventricle]], without new [[ventricular arrhythmias]] or [[Second degree AV block|second-]] or [[Third degree AV block|third-degree]] [[heart block]], that responds to usual care within 1 to 2 weeks. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
 
|-
The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''3.''' EMB may be considered in the setting of [[heart failure]] associated with unexplained [[Hypertrophic cardiomyopathy|hypertrophic cardiomyopathy (HCM)]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
 
|-
OR
|bgcolor="LemonChiffon"| <nowiki>"</nowiki>'''4.''' EMB may be considered in the setting of suspected [[Arrhythmogenic right ventricular dysplasia|arrhythmogenic right ventricular dysplasia (ARVD/C)]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
 
|-
The diagnosis of [disease name] is based on the [criteria name] criteria, which includes [criterion 1], [criterion 2], and [criterion 3].
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''5.''' EMB may be considered in the setting of unexplained unexplained [[ventricular arrhythmias]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki>
 
|}
OR
 
[Disease name] may be diagnosed at any time if one or more of the following criteria are met:  
* Criteria 1
* Criteria 2
* Criteria 3
 
OR
 
'''IF there are clear, established diagnostic criteria'''
 
The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].
 
OR
 
The diagnosis of [disease name] is based on the [criteria name] criteria, which include [criterion 1], [criterion 2], and [criterion 3].
 
OR
 
The diagnosis of [disease name] is based on the [definition name] definition, which includes [criterion 1], [criterion 2], and [criterion 3].


OR
==References==
{{Reflist|2}}


'''IF there are no established diagnostic criteria'''
[[Category:Cardiology]]
[[Category:Disease]]
[[Category:Emergency medicine]]
[[Category:Intensive care medicine]]
[[Category:Medicine]]
[[Category:Primary care]]
[[Category:Up-To-Date]]
[[Category:Up-To-Date cardiology]]


There are no established criteria for the diagnosis of [disease name].
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}


==References==
==References==

Revision as of 15:44, 18 December 2019

Myocarditis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Adrenergic Myocarditis
Giant Cell Myocarditis

Causes

Differentiating Myocarditis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myocarditis diagnostic study of choice On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Google Images

American Roentgen Ray Society Images of Myocarditis diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myocarditis diagnostic study of choice

CDC on Myocarditis diagnostic study of choice

Myocarditis diagnostic study of choice in the news

Blogs on Myocarditis diagnostic study of choice

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Myocarditis diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-In-Chief: Varun Kumar M.B.B.S., Maliha Shakil, M.D. [2]


Diagnostic Study of Choice

Study of choice

Endomyocardial Biopsy

  • The Heart Failure Society of America recommends that performance of endomyocardial biopsy should be considered when cardiac function deteriorates acutely with an unknown etiology that is unresponsive to medical therapy (Strength of Evidence = B).[1]
  • Non-specific findings such as hypertrophy, cell loss, and fibrosis may be noted on biopsy. However, biopsy findings that significantly impact patient management have not been conclusively established.[2] Although inflammatory changes in the myocardium may be detected in viral myocarditis, the majority of patients with biopsy proven myocarditis improve with supportive therapy alone without the need for antiviral or anti-inflammatory treatment.[3] Endomyocardial biopsy has a low sensitivity and specificity which could be explained by the focal and transient nature of the inflammatory infiltrates.[4][5]

Standardizing the Interpretation of Endomyocardial Biopsies: The Dallas Criteria

Histologically, both active inflammatory infiltrate within the myocardium and associated myocyte necrosis (the Dallas pathologic criteria) are present in myocarditis. Despite its limitations, the Dallas criteria have established uniform histologic criteria diagnosing myocarditis and have substantially reduced the variability in diagnosing the disease. Some of the criteria are as follows:[6]

“

Active myocarditis:

  • The presence of an inflammatory infiltrate of the myocardium with necrosis and/or degeneration of adjacent myocytes not typical of the ischaemic damage associated with coronary artery disease.

Borderline myocarditis:

  • The presence of an inflammatory infiltrate of the myocardium without necrosis or degeneration of adjacent myocytes.
 ”

Scenarios in Which Endomyocardial Biopsy May Be Useful[7][8]

Complications of Endomyocardial Biopsy

  • Complications may be as high as 6% as observed in a series where 546 patients with cardiomyopathy underwent right ventricular endomyocardial biopsy.[10] Several other studies reported the incidence of complications to be 0.5 to 1.5%.[11][12]
  • Complications of endomyocardial biopsy include:[11][13]

2009 ACC/AHA Focused Update and 2005 Guidelines for the Diagnosis and Management of Chronic Heart Failure in the Adult (DO NOT EDIT) [14]

Endomyocardial Biopsy in Patients Presenting With Heart Failure (DO NOT EDIT) [14]

Class III (No Benefit)
" 1. Endomyocardial biopsy should not be performed in the routine evaluation of patients with heart failure.[13] (Level of Evidence: C) "
Class IIa
"1. Endomyocardial biopsy can be useful in patients presenting with heart failure when a specific diagnosis is suspected that would influence therapy.[13] (Level of Evidence: C) "

2007 AHA/ACCF/ESC Scientific Statement: The Role of Endomyocardial Biopsy (EMB) in Fourteen Clinical Scenarios[13]

Class I
"1. EMB should be performed in the setting of unexplained, new-onset heart failure of less than 2 weeks’ duration associated with a normal-sized or dilated left ventricle and hemodynamic compromise. (Level of Evidence: B) "
"2. EMB should be performed in the setting of unexplained, new-onset heart failure of 2 weeks’ to 3 months’ duration associated with a dilated left ventricle and new ventricular arrhythmias, second- or third-degree heart block, or failure to respond to usual care within 1 to 2 weeks. (Level of Evidence: B) "
Class III (No Benefit)
"1. EMB should not be performed in the setting of unexplained atrial fibrillation. (Level of Evidence: C) "
Class IIa
"1. EMB is reasonable in the clinical setting of unexplained heart failure of more than 3 months’ duration associated with a dilated left ventricle and new ventricular arrhythmias, second- or third-degree heart block, or failure to respond to usual care within 1 to 2 weeks. (Level of Evidence: C) "
"2. EMB is reasonable in the setting of unexplained heart failure associated with a dilated cardiomyopathy (DCM) of any duration associated with suspected allergic reaction and/or eosinophilia. (Level of Evidence: C) "
"3. EMB is reasonable in the setting of unexplained heart failure associated with suspected anthracycline cardiomyopathy. (Level of Evidence: C) "
"4. EMB is reasonable in the setting of heart failure associated with unexplained restrictive cardiomyopathy. (Level of Evidence: C) "
"5. EMB is reasonable in the setting of suspected cardiac tumors. (Level of Evidence: C) "
"6. EMB is reasonable in the setting of unexplained cardiomyopathy in children. (Level of Evidence: C) "
Class IIb
"1. EMB may be considered in the setting of unexplained, new-onset heart failure of 2 weeks’ to 3 months’ duration associated with a dilated left ventricle, without new ventricular arrhythmias or second- or third-degree heart block, that responds to usual care within 1 to 2 weeks. (Level of Evidence: B) "
"2. EMB may be considered in the setting of unexplained heart failure of more than 3 months’ duration associated with a dilated left ventricle, without new ventricular arrhythmias or second- or third-degree heart block, that responds to usual care within 1 to 2 weeks. (Level of Evidence: C) "
"3. EMB may be considered in the setting of heart failure associated with unexplained hypertrophic cardiomyopathy (HCM). (Level of Evidence: C) "
"4. EMB may be considered in the setting of suspected arrhythmogenic right ventricular dysplasia (ARVD/C). (Level of Evidence: C) "
"5. EMB may be considered in the setting of unexplained unexplained ventricular arrhythmias. (Level of Evidence: C) "

References

  1. ↑ Heart Failure Society of America. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA; et al. (2010). "HFSA 2010 Comprehensive Heart Failure Practice Guideline". J Card Fail. 16 (6): e1–194. doi:10.1016/j.cardfail.2010.04.004. PMID 20610207. Unknown parameter |http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom= ignored (help)
  2. ↑ Chow LC, Dittrich HC, Shabetai R (1988). "Endomyocardial biopsy in patients with unexplained congestive heart failure". Ann Intern Med. 109 (7): 535–9. PMID 3421562.
  3. ↑ Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME; et al. (1995). "A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators". N Engl J Med. 333 (5): 269–75. doi:10.1056/NEJM199508033330501. PMID 7596370.
  4. ↑ Mahrholdt H, Goedecke C, Wagner A, Meinhardt G, Athanasiadis A, Vogelsberg H; et al. (2004). "Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology". Circulation. 109 (10): 1250–8. doi:10.1161/01.CIR.0000118493.13323.81. PMID 14993139. Unknown parameter |http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom= ignored (help)
  5. ↑ Hauck AJ, Kearney DL, Edwards WD (1989). "Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error". Mayo Clin Proc. 64 (10): 1235–45. PMID 2593714.
  6. ↑ Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ; et al. (1987). "Myocarditis. A histopathologic definition and classification". Am J Cardiovasc Pathol. 1 (1): 3–14. PMID 3455232.
  7. ↑ Wu LA, Lapeyre AC, Cooper LT (2001). "Current role of endomyocardial biopsy in the management of dilated cardiomyopathy and myocarditis". Mayo Clin Proc. 76 (10): 1030–8. PMID 11605687.
  8. ↑ Magnani JW, Dec GW (2006). "Myocarditis: current trends in diagnosis and treatment". Circulation. 113 (6): 876–90. doi:10.1161/CIRCULATIONAHA.105.584532. PMID 16476862. Unknown parameter |http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom= ignored (help)
  9. ↑ Cooper LT, Berry GJ, Shabetai R (1997). "Idiopathic giant-cell myocarditis--natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators". N Engl J Med. 336 (26): 1860–6. doi:10.1056/NEJM199706263362603. PMID 9197214.
  10. ↑ Deckers JW, Hare JM, Baughman KL (1992). "Complications of transvenous right ventricular endomyocardial biopsy in adult patients with cardiomyopathy: a seven-year survey of 546 consecutive diagnostic procedures in a tertiary referral center". J Am Coll Cardiol. 19 (1): 43–7. PMID 1729344.
  11. ↑ 11.0 11.1 Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C, Athanasiadis A; et al. (2010). "Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance". Circulation. 122 (9): 900–9. doi:10.1161/CIRCULATIONAHA.109.924167. PMID 20713901.
  12. ↑ Holzmann M, Nicko A, Kühl U, Noutsias M, Poller W, Hoffmann W; et al. (2008). "Complication rate of right ventricular endomyocardial biopsy via the femoral approach: a retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period". Circulation. 118 (17): 1722–8. doi:10.1161/CIRCULATIONAHA.107.743427. PMID 18838566.
  13. ↑ 13.0 13.1 13.2 13.3 Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U; et al. (2007). "The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology". Circulation. 116 (19): 2216–33. doi:10.1161/CIRCULATIONAHA.107.186093. PMID 17959655.
  14. ↑ 14.0 14.1 Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG et al. (2009) 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119 (14):1977-2016. DOI:10.1161/CIRCULATIONAHA.109.192064 PMID: 19324967


Template:WikiDoc Sources

References

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Myocarditis_diagnostic_study_of_choice&oldid=1592202"